Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

235.50 -0.78 (-0.33%)

Streaming Delayed Price Updated: 10:36 AM EST, Nov 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

90 91 Next >

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

Via FinancialNewsMedia

The Smartest Dividend Stocks to Buy With $1,000 Right Now ↗

December 26, 2024

Via The Motley Fool

Looking Into AbbVie's Recent Short Interest ↗

December 25, 2024

Via Benzinga

Introducing the "Dividend Seven" Stocks ↗

December 24, 2024

Via The Motley Fool

$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today ↗

December 24, 2024

Via Benzinga

Is AbbVie Stock a Buy? ↗

December 23, 2024

Via The Motley Fool

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

From FN Media Group LLC

Via GlobeNewswire

Schwab US Dividend Equity ETF Reverses In December: What's Going On? ↗

December 23, 2024

The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund:

Via Benzinga

Topics ETFs

2 Excellent Dividend Stocks to Buy on the Dip ↗

December 23, 2024

Via The Motley Fool

Analyst Scoreboard: 19 Ratings For AbbVie ↗

December 10, 2024

Via Benzinga

Check Out What Whales Are Doing With ABBV ↗

December 09, 2024

Via Benzinga

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗

December 22, 2024

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Via Benzinga

2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗

December 22, 2024

Via The Motley Fool

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally ↗

December 21, 2024

Via The Motley Fool

2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond ↗

December 19, 2024

Via The Motley Fool

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields ↗

December 17, 2024

Via Benzinga

Check Out What Whales Are Doing With ABBV ↗

December 04, 2024

Via Benzinga

Spotlight on AbbVie: Analyzing the Surge in Options Activity ↗

November 29, 2024

Via Benzinga

AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? ↗

December 17, 2024

AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025.

Via Investor's Business Daily

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

December 15, 2024

These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth.

Via The Motley Fool

Neurocrine Wins FDA Approval For Genetic Disorder Drug ↗

December 13, 2024

The company can launch within a week, says Chief Executive Kyle Gano.

Via Investor's Business Daily

1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever ↗

December 12, 2024

Via The Motley Fool

Topics Stocks

AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study ↗

December 09, 2024

AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom improvement and safety.

Via Benzinga

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts ↗

December 04, 2024

Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.

Via Benzinga

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields ↗

December 03, 2024

Via Benzinga

3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer ↗

December 03, 2024

Via The Motley Fool

It’s Been A Tough Month For Healthcare Stocks ↗

December 02, 2024

It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.

Via Talk Markets

Topics ETFs Stocks / Equities

3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later ↗

December 01, 2024

Via The Motley Fool

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

November 30, 2024

Via The Motley Fool

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce ↗

November 26, 2024

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

90 91 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.